↓ Skip to main content

Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose

Overview of attention for article published in Clinical and Translational Allergy, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter
11 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose
Published in
Clinical and Translational Allergy, December 2015
DOI 10.1186/s13601-015-0088-1
Pubmed ID
Authors

Pascal Demoly, Gianni Passalacqua, Moises A. Calderon, Tarik Yalaoui

Abstract

Sublingual immunotherapy (SLIT) is an effective and well-tolerated method of treating allergic respiratory diseases associated with seasonal and perennial allergens. In contrast to the subcutaneous route, SLIT requires a much greater amount of antigen to achieve a clinical effect. Many studies have shown that SLIT involves a dose-response relationship, and therefore it is important to use a proven clinically effective dose from the onset of treatment, because low doses are ineffective and very high doses may increase the risk of side effects. A well-defined standardization of allergen content is also crucial to ensure consistent quality, potency and appropriate immunomodulatory action of the SLIT product. Several methods of measuring antigenicity are used by manufacturers of SLIT products, including the index of reactivity (IR), standardized quality tablet unit, and bioequivalent allergy unit. A large body of evidence has established the 300 IR dose of SLIT as offering optimal efficacy and tolerability for allergic rhinitis due to grass and birch pollen and HDM, and HDM-induced moderate, persistent allergic asthma. The 300 IR dose also offers consistency of dosing across a variety of different allergens, and is associated with higher rates of adherence and patient satisfaction. Studies in patients with grass pollen allergies showed that the 300 IR dose has a rapid onset of action, is effective in both adults and children in the short term and, when administered pre-coseasonally in the long term, and maintains the clinical benefit, even after cessation of treatment. In patients with HDM-associated AR and/or asthma, the 300 IR dose also demonstrated significant improvements in symptoms and quality of life, and significantly decreased use of symptomatic medication. The 300 IR dose is well tolerated, with adverse events generally being of mild or moderate severity, declining in frequency and severity over time and in the subsequent courses. We discuss herein the most important factors that affect the selection of the optimal dose of SLIT with natural allergens, and review the rationale and evidence supporting the use of the 300 IR dose.

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 40 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 20%
Other 4 10%
Researcher 4 10%
Student > Ph. D. Student 4 10%
Professor 3 7%
Other 8 20%
Unknown 10 24%
Readers by discipline Count As %
Medicine and Dentistry 18 44%
Agricultural and Biological Sciences 4 10%
Nursing and Health Professions 3 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Sports and Recreations 1 2%
Other 3 7%
Unknown 11 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2018.
All research outputs
#3,997,742
of 17,039,068 outputs
Outputs from Clinical and Translational Allergy
#218
of 508 outputs
Outputs of similar age
#80,859
of 373,678 outputs
Outputs of similar age from Clinical and Translational Allergy
#4
of 34 outputs
Altmetric has tracked 17,039,068 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 508 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 373,678 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.